ADAMTS-20 inhibitors are a class of chemical compounds that selectively inhibit the activity of ADAMTS-20, a member of the ADAMTS (A Disintegrin and Metalloproteinase with Thrombospondin motifs) family of proteases. This enzyme plays a role in the proteolytic processing of extracellular matrix components, particularly versican, which is a large chondroitin sulfate proteoglycan. The inhibition of ADAMTS-20 affects the degradation of versican and potentially other substrates, influencing extracellular matrix dynamics and remodeling. Structurally, ADAMTS-20 inhibitors often consist of small molecules that can interact with the catalytic zinc-binding motif present in the enzyme's metalloprotease domain, interfering with its function.
In addition to the metalloprotease domain, ADAMTS-20 contains several ancillary domains, such as thrombospondin type-1 repeats, that are involved in substrate recognition and enzyme localization within the extracellular matrix. Effective inhibitors must target not only the catalytic activity but also maintain selectivity, minimizing interactions with other ADAMTS family members that share similar structural motifs. These inhibitors are valuable in studying the biochemical pathways regulated by ADAMTS-20, especially in processes such as cell migration, tissue development, and extracellular matrix homeostasis. Due to the enzyme's multifaceted role, ADAMTS-20 inhibitors are tools for dissecting complex biological systems related to matrix turnover and cellular signaling. Their design often incorporates knowledge from structural biology and computational chemistry to optimize interactions with specific domains of the enzyme.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Batimastat | 130370-60-4 | sc-203833 sc-203833A | 1 mg 10 mg | $175.00 $370.00 | 24 | |
Batimastat may inhibit ADAMTS-20 by targeting its metalloproteinase domain, affecting protein interactions and cleavage. | ||||||
GM 6001 | 142880-36-2 | sc-203979 sc-203979A | 1 mg 5 mg | $75.00 $265.00 | 55 | |
GM6001 may inhibit the proteolytic activity of ADAMTS-20, potentially affecting ECM composition and cell behavior. | ||||||
Marimastat | 154039-60-8 | sc-202223 sc-202223A sc-202223B sc-202223C sc-202223E | 5 mg 10 mg 25 mg 50 mg 400 mg | $165.00 $214.00 $396.00 $617.00 $4804.00 | 19 | |
Marimastat could inhibit ADAMTS-20 activity, affecting matrix protein cleavage and tissue remodeling. | ||||||
SB-3CT | 292605-14-2 | sc-205847 sc-205847A | 1 mg 5 mg | $100.00 $380.00 | 15 | |
SB-3CT may target the metalloproteinase domain of ADAMTS-20, affecting its enzymatic activity in the ECM. | ||||||
Prinomastat | 192329-42-3 | sc-507449 | 5 mg | $190.00 | ||
Prinomastat could interfere with the enzymatic activity of ADAMTS-20, impacting ECM composition. | ||||||
Ro 32-3555 | 190648-49-8 | sc-296277 | 10 mg | $413.00 | 2 | |
Ro 32-3555 could inhibit ADAMTS-20, potentially affecting cellular adhesion and migration in the ECM. | ||||||